Advertisement



Drug Recalls

Last updated

Every drug recall in FDA enforcement reports from the last three years, plus older recalls that are still open. Filter by severity, status or medicine, and check the lot numbers on your package.

0 Class I (most serious) drug recalls reported in the last 30 days.

2 recalls

  • Class II Terminated

    Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP, 0.5 mg & 3mg/3mL unit-dose vials, packaged in carton containing 30 vials ( 6 pouches of 5 – 3 mL vials), Rx only, Manufactured by: Cipla Ltd., Indore SEZ…

    Reason: Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.

    Cipla USA, Inc. · Ipratropium Bromide and Albuterol Sulfate

    Lots, distribution and details
    Product
    Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USP, 0.5 mg & 3mg/3mL unit-dose vials, packaged in carton containing 30 vials ( 6 pouches of 5 – 3 mL vials), Rx only, Manufactured by: Cipla Ltd., Indore SEZ, Pithampur, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-173-53
    Lots / codes
    Lot # IA30390, Exp 4/30/2025, IA30517, Exp 6/30/ 2025
    Distribution
    USA nationwide.
    Quantity
    59244/3ml FFS packs
    Recall started
    March 26, 2024 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0471-2024
  • Class II Terminated

    Ipratropium Bromide and Albuterol Sulfate Inhalation Solution (0.5 mg/3 mg per 3 mL), 60 x 3 mL Sterile Unit-Dose Vials (2 pouches of 30 – 3 mL vials each), Manufactured By: The Ritedose Corporation, Columbia, SC 29203;…

    Reason: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

    CARDINAL HEALTHCARE · Ipratropium Bromide and Albuterol Sulfate

    Lots, distribution and details
    Product
    Ipratropium Bromide and Albuterol Sulfate Inhalation Solution (0.5 mg/3 mg per 3 mL), 60 x 3 mL Sterile Unit-Dose Vials (2 pouches of 30 – 3 mL vials each), Manufactured By: The Ritedose Corporation, Columbia, SC 29203; Distributed By: Cipla USA Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-840-64
    Lots / codes
    Batch 21C56
    Distribution
    Nationwide USA
    Quantity
    2 cartons
    Recall started
    January 26, 2022 (Voluntary: Firm initiated)
    Severity
    Could cause temporary or medically reversible health problems; serious harm is unlikely.
    FDA recall number
    D-0161-2024

Have this medicine at home? Compare the lot number and expiry date on your package with the recall. Do not stop taking a prescribed medicine on your own — stopping suddenly can be riskier than the recalled lot. Your pharmacist can check it and usually swap it for an unaffected one.

What the recall classes mean

  • Class I Most serious: use could cause serious health problems or death.
  • Class II Could cause temporary or medically reversible health problems; serious harm is unlikely.
  • Class III Not likely to cause health problems — for example a labelling or packaging fault.

Source: FDA Enforcement Report, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.

Advertisement